Thus, Sema6D forward signaling might be a vital biomarker for ICI resistance and a promising therapeutic target in a broad range of cancer types, including HNSCC, to improve ICI efficacy by inducing CD8+ T cell infiltration into tumors. Here, CD8A is linked to cancer.